Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye comments on OncoZenge’s announcement of appointing LINK Medical as CRO for its pivotal phase III trial with BupiZenge.</li><li>We view this as a natural and strategically sound step following the feasibility study conducted by LINK, ensuring both continuity and regional expertise as the company advances toward European market approval.</li></ul>

Redeye comments on OncoZenge’s announcement of appointing LINK Medical as CRO for its pivotal phase III trial with BupiZenge.We view this as a natural and strategically sound step following the feasibility study conducted by LINK, ensuring both continuity and regional expertise as the company advances toward European market approval.

OncoZenge: Appoints LINK Medical as CRO for the phase III study

Oncozenge

OncoZenge: Appoints LINK Medical as CRO for the phase III study